For example, semaglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist, has demonstrated reliable weight loss effects in treating obesity and diabetes (Knudsen and Lau, 2019; Davies et al., 2021). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.